Ocrevus (ocrelizumab) - Nazari mai inganci

Ocrevus (ocrelizumab) magani ne na halitta wanda ake amfani dashi don magance sclerosis da yawa (MS) da rheumatoid arthritis (RA). FDA ta amince da miyagun ƙwayoyi a cikin 2017 don maganin MS kuma a cikin 2021 don maganin RA.

Ayyukan Ocrevus ya dogara ne akan toshe furotin CD20, wanda ke samuwa a saman wasu kwayoyin halitta na tsarin rigakafi, ciki har da kwayoyin da ke taka muhimmiyar rawa wajen bunkasa MS da RA. Toshe furotin CD20 zai iya rage ayyukan tsarin rigakafi da rage kumburi wanda ke haifar da lalacewar nama.

An gudanar da bincike kan tasirin Ocrevus a cikin maganin MS da RA na shekaru da yawa. Ɗaya daga cikin binciken farko, wanda aka buga a cikin The Lancet a cikin 2017, an kira shi "Inganci da aminci na Ocrevus a cikin sclerosis na ci gaba na farko." An gudanar da binciken akan marasa lafiya sama da 700 waɗanda suka karɓi Ocrevus ko placebo na makonni 96. Sakamakon ya nuna cewa Ocrevus ya rage girman ci gaban MS idan aka kwatanta da placebo.

Wani binciken da aka buga a cikin New England Journal of Medicine a cikin 2017 ya bincika ingancin Ocrevus a cikin sake dawowa-remitting Multi sclerosis (RRMS). An gudanar da binciken akan fiye da marasa lafiya 1300 da suka karbi Ocrevus ko wani magani don maganin RRMS. Sakamakon ya nuna cewa Ocrevus ya rage yawan sake dawowa a cikin marasa lafiya idan aka kwatanta da sauran magungunan.

An kuma gudanar da bincike kan ingancin Ocrevus a cikin RA. Ofaya daga cikinsu, wanda aka buga a cikin The Lancet a cikin 2019, yayi nazarin ingancin Ocrevus a cikin RA, wanda shine ɗayan mafi tsanani.